Showing 5451-5460 of 8923 results for "".
- Dermira's Investigational AD Drug Performs Well in Phase 2b Trial, Shares Skyrockethttps://practicaldermatology.com/news/ready-for-phase-3-dermiras-investigational-ad-drug-performs-well-in-phase-2b-trial/2459969/All three doses of Dermira, Inc.’s lebrikizumab showed greater improvements in the Eczema Area and Severity Index in a new Phase 2b dose-ranging study of adults with moderate-to-severe atopic dermatitis, and shares of D
- Study: Port Wine Stain Laser Treatment Is Safe and Effective in Infants Without Anesthesiahttps://practicaldermatology.com/news/study-port-wine-stain-laser-treatment-is-safe-and-effective-in-infants-without-anesthesia/2459974/Recent concerns about the repetitive use of general anesthesia in children younger than 3 have placed greater importance on the controversy surrounding the timing of port-wine stain laser treatment, but a new
- History of Dermatology Society Names Samuel J. Zakon Awardeehttps://practicaldermatology.com/news/history-of-dermatology-society-names-samuel-j-zakon-awardee/2459972/Frederick C. Gaede, BA, MAS, has received the Samuel J. Zakon Award in the History of Dermatology for his article entitled “Henry Granger Piffard, MD and His Photogenic Pistol Cartridges.” The Award was announced at the forty-sixth annual meeting of the History of Dermatology Society
- Calling All Students: Ortho Dermatologics Now Accepting Applications for the 2019 Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/calling-all-students-ortho-dermatologics-now-accepting-applications-for-the-2019-aspire-higher-scholarship-program/2459978/Ortho Dermatologics is accepting applications for its 2019 Aspire Higher scholarship program, which will award $90,000 total in scholarships to nine students who have been treated for a dermatologic condition. Students can apply for the Aspire Higher scholarship through April 26, 2
- FDA Approves Dupixent for Moderate to Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-approves-dupixent-for-moderate-to-severe-atopic-dermatitis-in-adolescents/2459975/The FDA has approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged 12 through 17 whose disease is not adequately controlled with topical prescription
- 2019 NewBeauty Awards: Alastin's TransFORM Body Treatment Acknowledged for Innovationhttps://practicaldermatology.com/news/2019-newbeauty-awards-alastins-transform-body-treatment-acknowledged-for-innovation/2459977/ALASTIN Skincare, Inc’s TransFORM Body Treatment has been awarded a 2019 NewBeauty Award in the innovations category. NewBeauty acknowledges the best products, treatments and trends in cosmetics and aesthetics with their innovation category described as, "the future is now
- Biopelle Launches Emepelle to Address Estrogen Deficient Skinhttps://practicaldermatology.com/news/biopelle-launches-emepelle-to-address-estrogen-deficient-skin/2459979/Biopelle, Inc. has launched Emepelle, the first and only clinically proven skincare line that safely and effectively helps address Estrogen Deficient Skin (EDS). Emepelle features MEP Technology, a patented, specifically designed ingredient that helps
- L'Oréal Partners with uBiome to Advance New Research on the Skin's Microbiomehttps://practicaldermatology.com/news/loral-partners-with-ubiome-to-advance-new-research-on-the-skins-microbiome/2459980/L'Oréal’s tech Incubator is joining forces with uBiome, a Silicon Valley-based microbiome research venture. The partnership was announced at L'Oréal's "Know Your Sk
- New Mouse Model Validates How “Good” and “Bad” Bacteria Affect Acnehttps://practicaldermatology.com/news/new-mouse-model-validates-how-good-and-bad-bacteria-affect-acne/2459981/Researchers at University of California San Diego School of Medicine, Cedars-Sinai and UCLA have developed a new mouse model that closely resembles human acne by adding one new factor — a synthetic sebum. Researchers have long believed that Propionibacterium acnes causes ac
- Almirall: Positive Data for KX2-391 for AKs; ThermiGen to be Divestedhttps://practicaldermatology.com/news/almirall-positive-data-for-kx2-391-for-aks-thermigen-to-be-divested/2459986/Results from two Phase III studies of KX2-391, also known as KX-01 ointment, in the treatment of actinic keratosis show positive results. The findings have been presented at the 2019 American Academy of Dermatology Annual Meeting in Washington, DC and were